Allergan, Inc. v. Sandoz Inc, No. 2:09-cv-00097 (E.D. Tex. Aug. 25, 2011)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Pending be fore the court is Defendants Sandoz Inc. ‟s (”Sandoz”); Alcon Laboratories, Inc.‟s, Alcon Research Ltd. ‟s, Alcon Research, Inc. ‟s, and Falcon Pharmaceuticals, Ltd. ‟s (“Alcon”); Apotex Inc. ‟s and Apotex Corp. ‟s (“Apotex”); and Watson Laboratories, Inc. ‟s (“Watson”) (collectively, “Defendants ”) motion for summary judgment of non -infringement of claims 1-3 of Allergan Inc.‟s (“Allergan”) U.S. Patent No. 7,030,149 (“the „149 patent”) . (D.I.